Hormone Receptor-Positive Breast Cancer Management

Introduction to Hormone Receptor-Positive Breast Cancer

• The National Comprehensive Cancer Network recommends that hormone receptor-positive tumors be treated with endocrine therapy, which provides significant mortality reduction with relatively low toxicity, making these cancers highly treatable 1, 3
• Patients with ER-positive tumors have access to multiple effective endocrine therapy options including tamoxifen and aromatase inhibitors that substantially reduce recurrence risk 1, 2

Treatment of Hormone Receptor-Positive Breast Cancer

• The American College of Surgeons and other medical organizations suggest that higher percentages of hormone receptor positivity correlate with decreased local recurrence and improved overall survival, although the exact correlation may vary 3
• The cutoff for hormone receptor positivity is as low as 1% positive-staining cells, and even these low levels are associated with significant clinical response to endocrine therapy 3

Treatment of Node-Positive Breast Cancer

• The National Comprehensive Cancer Network guidelines indicate that lymph node-positive patients are candidates for chemotherapy regardless of hormone receptor status (category 1 recommendation) 1, 2
• Patients with 4 or more positive nodes require postmastectomy radiation therapy to chest wall and regional lymph nodes (category 1) 4
• Even with 1-3 positive nodes, regional nodal irradiation should be strongly considered based on risk estimates 4

Clinical Decision-Making

• For hormone receptor-positive, node-negative disease, tumors ≤0.5 cm: Endocrine therapy alone may be sufficient; systemic chemotherapy provides minimal incremental benefit 2, 5
• For node-positive disease (regardless of hormone receptor status), all patients require chemotherapy (category 1) 1, 2
• If hormone receptor-positive, add endocrine therapy after chemotherapy completion 1, 2